Clinic business

Vivos Inc. Announces New Regional IsoPet® Precision Radiotherapy Clinic for Equine Therapy | National

Richland WA, Aug. 16, 2022 (GLOBE NEWSWIRE) —Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that it has certified New England Equine Practice in Patterson, NY to administer Precision Radionuclide IsoPet® Therapy for the treatment of solid tumors in horses.

IsoPet® is a next-generation treatment option, providing same-day therapy, using a relatively low activity to deliver a high therapeutic dose that remains at the injection site without contamination in urine or feces.

As we gain experience at our equine sites and gain the trust of regulators, we intend to expand their radioactive material handling license to allow for the use of a mobile therapy vehicle. Isopet® which can treat horses in their farm of origin. This is an important feature as horses should not be trailed for longer than eight hours or they may develop serious medical respiratory problems known as ‘trailer fever’ the next day.

Dr. Korenko said: “We are in active discussions regarding the opening of additional equine clinics and are delighted to offer Isopet® as a breakthrough treatment option for the treatment of solid tumors in horses.

We are also pleased to report that our first Isopet® equine therapy demonstration at the University of Missouri Regional Clinic (Summer Solstice) remains cancer free after fifteen months.

About Vivos Inc. (OTCQB: RDGL)

Vivos Inc. has developed a Yttrium-90-based precision radionuclide injectable brachytherapy device for the treatment of tumors in animals (IsoPet®) and humans (RadioGel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entry cutaneous dose and treatment-associated side effects that characterize external beam radiation therapy. This feature allows for the safe delivery of higher doses needed to treat unresectable and radiation-resistant cancers.

RadioGel™ is a liquid hydrogel containing tiny particles of yttrium-90 phosphate that can be delivered directly into a tumor. The hydrogel is a carrier of yttrium-90 at room temperature that gels into tumor interstitial spaces after injection to hold radiation sources securely in place. Yttrium-90’s short-range beta radiation localizes the dose to the treatment area so that normal organs and tissues are not affected.

RadioGel™ also has a short half-life – delivering over 90% of its therapeutic radiation in 10 days. This compares favorably to other available treatment options that require up to six weeks or more to deliver a full cycle of radiation therapy. The therapy can be safely administered as an outpatient procedure and the patient can go home without worrying about the radiation dose to family members later.

The IsoPet® Solutions division has used university veterinary hospitals to demonstrate the safety and therapeutic efficacy of various animal cancers. Feline sarcoma testing at Washington State University was completed in 2018 and canine soft tissue sarcoma testing at the University of Missouri was completed in 2019.

In 2018, the Company obtained confirmation from the FDA’s Center for Veterinary Medicine that IsoPet® is classified as a medical device based on its intended use and the means by which it achieves its purpose. The FDA also reviewed product labeling which included canine and feline sarcomas as initial indications for use. The FDA does not require premarket approval for veterinary devices, so no additional approval is required. After the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet® to university veterinary hospitals and private veterinary clinics.

IsoPet® for animal treatment uses the same technology as RadioGel™ for human treatment. The Food and Drug Administration has advised using different product names to avoid confusion and cross-use.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may”, “will”, “should”, “plan”, “expect”. to, “plans”, “continues”, “estimates”, “plans”, “intends” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company’s ability to successfully execute its broader business strategy, including entering into definitive agreements with suppliers, business partners and customers; general economic and business conditions, the effects of continuing geopolitical unrest and regional conflict, competition, changes in technology and marketing methods, delays in the completion of various engineering and manufacturing programs, changes in customer ordering patterns, changes in product lineup, continued success in technical advancements and delivery of technological innovations, component shortages, production delays due to performance quality issues with components outsourced, regulatory requirements and the ability to comply with them, governmental agency rules and changes, and various other factors beyond the Company’s control.


Vivos Inc.

Michael K. Korenko, Sc.D.

President and CEO

Copyright 2022 GlobeNewswire, Inc.